Abstract

Background: In Tanah Bumbu District, South Kalimantan, Indonesia, there was 59 dengue hemorrhagic fever (DHF) cases with one death occurring in 2016. For the treatment of DHF inpatients, at Simpang Empat Primary Health Center, the Standardized Herbal Medicines (SHM) are used in addition to WHO standards. Objective: determine cost-effectivity of SHM for DHF patients at Simpang Empat Primary Health Center. Methods: Data were collected retrospectively from the medical records of DHF in 2015. Data were divided into two: DHF patients treated according to WHO standard, and data on DHF patients treated according to WHO standard plus SHM. The Health Care Perspective is used to analyze the cost effectiveness. Results: Treatment using both the WHO standard and the SHM intervention, show that two kinds of therapy were effective in increasing platelet levels. However, the SHM intervention has a predominant position in the cost-effectivity table. Conclusion: The use of SHM in DHF therapy is not recommended as an alternative therapy because it shows higher cost than without SHM although both have similar effectivity in increasing platelet levels.